A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

ClinicalTrials.gov ID: NCT01268150

Public ClinicalTrials.gov record NCT01268150. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the efficacy and safety of single-agent eribulin mesylate for first-line treatment of subjects with locally recurrent or metastatic breast cancer.

Study identification

NCT ID: NCT01268150
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Eisai Inc.; Industry
Enrollment: 56 participants

Conditions and interventions

Conditions

Interventions

Eribulin mesylate Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2011 (Type not available)
Primary completion: Mar 2012 (Actual)
Completion: Aug 2013 (Actual)
Last update posted: Jun 22, 2023

2011 – 2013

United States locations

U.S. sites: 17
U.S. states: 10
U.S. cities: 16

Facility	City	State	ZIP	Site status
University of Miami	Miami	Florida	33136	—
Augusta Oncology Associates	Augusta	Georgia	30901	—
Central Georgia Cancer Care	Macon	Georgia	31088	—
Northwest Georgia Oncology Centers, P.C.	Marietta	Georgia	30060	—
Central Indiana Cancer Centers	Indianapolis	Indiana	46219	—
Missouri Cancer Associates	Columbia	Missouri	65201	—
Hematology Oncology Centers of Northern Rockies	Billings	Montana	59101	—
New York Oncology Hematology, P.C.	Albany	New York	12206	—
Weill Cornell Medical Center	New York	New York	10021	—
Northwest Cancer Specialists, P.C.	Portland	Oregon	97225	—
The West Clinic	Memphis	Tennessee	38120	—
Texas Oncology- Bedford	Bedford	Texas	76022	—
Texas Oncology - Medical City Dallas	Dallas	Texas	75230-2510	—
Texas Oncology-Dallas Presbyterian Hospital	Dallas	Texas	75231	—
Cancer Care Centers of South Texas	San Antonio	Texas	78217	—
Texas Oncology- Tyler	Tyler	Texas	75702	—
Columbia Basin Hematology and Oncology	Kennewick	Washington	99336	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01268150, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 22, 2023 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01268150 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →